Key result
Recent genomic findings indicate that aberrant angiogenic signaling and MYC amplifications are key distinguishing features of angiosarcomas.
Aberrant angiogenic signaling and Myc amplification are key genomic features of angiosarcomas, which may help guide future personalized treatment options.
Answers are grounded in this paper and cite their sources.
May support targeted therapy trials in angiosarcoma; leaves open prospective validation of genomic biomarkers.
Angiosarcomas are very aggressive, rare malignant tumors that originate from vascular or lymphatic vessels and primarily occur following chemical exposure or radiation therapy. Tumor response to either chemotherapy, radiation, or novel anti-angiogenic therapeutics is very low, and because little is known regarding the aberrant signaling that controls these tumors, personalized treatment options for many of these patients are lacking. In this review, we summarize several recent findings regarding the genomics of angiosarcomas, including new discoveries regarding aberrant angiogenic signaling and Myc amplification as key features of this tumor type.
No takes yet. Share an insight, caveat, or question.
Vittal Kurisetty (2013) conducted a review in Angiosarcoma. Recent genomic findings indicate that aberrant angiogenic signaling and MYC amplifications are key distinguishing features of angiosarcomas.
Synapse has enriched 10 related papers. Consider them for comparative context: